Antengene Doses First Patient in Pivotal Phase III Study of ATG-022

Antengene Corporation Limited has administered the first dose to a patient in the company's pivotal Phase III CLINCH-3 study. The trial aims to assess the efficacy and safety of the drug candidate ATG-022 in patients with refractory esophageal cancer.

The CLINCH-3 study is a multi-center trial conducted across several countries. Its objective is to gather sufficient data to support a potential regulatory submission for ATG-022 as a treatment option for refractory esophageal cancer, a condition with limited current therapeutic alternatives.

Esophageal cancer presents a significant global health challenge, and treating refractory forms remains particularly difficult. ATG-022 is a therapeutic agent developed by Antengene that targets specific mechanisms driving cancer cell proliferation.

The company has previously reported positive outcomes from earlier clinical research phases of ATG-022. The progression of the CLINCH-3 study marks a key milestone in the drug's development pathway toward potential market entry.